| Name | Title | Contact Details |
|---|
Loretto is a Syracuse, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Stormont Vail Health is a nonprofit integrated health care system that has been serving the health care needs of northeast Kansas for more than 130 years. It is comprised of Stormont Vail Hospital, a 586-bed acute care Magnet®-designated hospital, and Cotton O`Neil Clinic, a multi-specialty physician group with more than 250 physicians. Nearly 5,000 employees provide care and support services for patients in the hospital and 35 other locations, including the Cotton O`Neil Heart Center, Cancer Center, Diabetes & Endocrinology Center, Digestive Health Center, Pediatrics clinics, 10 regional primary care clinics and six Express Care clinics. Stormont Vail Health is committed to its mission of improving the health of the community by being a national leader in providing compassionate, high-quality and efficient integrated care through collaboration that results in a healthier community. Stormont Vail Health is a member of the Mayo Clinic Care Network, a group of more than 40 health care organizations who have joined together to complement their local expertise with the knowledge and experience of Mayo Clinic health care professionals. Stormont Vail`s local partnerships include housing the Bachelor of Science in Nursing program of the Baker University School of Nursing, providing athletic training services to Washburn University Athletics and being a founding partner of the Powercat Health Partnership with Kansas State University and the Kansas Health Foundation.
Salina Regional Health Center offers rehabilitation services to a wide array of patients. We provide Physical Therapy, Occupational Therapy, Recreational Therapy, Speech Therapy, and Rehabilitation Nursing to many ages.
lcelyx was founded in 2010 with venture capital backing based on Gut Sensory Modulation (GSM) technology. Elcelyx`s proprietary, first-in-class Gut Sensory Modulators are delivered directly to the lower gut where they act on molecular targets to elicit physiological and pharmacological effects. The Elcelyx proprietary product candidate, NewMet for Type 2 diabetes is entering Phase 2b development and is a blockbuster opportunity designed to address the unmet needs in the oral anti-diabetic market. Elcelyx is led by an experienced management team and Board of Directors with track records of success in drug development and commercialization. Premier investors along with seasoned scientists and clinicians support the team. In September 2013, Elcelyx announced the formation of NaZura BioHealth Inc, a separate company established to focus on the development on non-NewMet assets.